The success of the COVID-19 mRNA vaccines has demonstrated the potential of RNA vaccines and therapies. Over the next decade, RNA is poised to become a central drug platform for treating a wide range of human diseases.
Accessible services include RNA design, plasmid amplification and linearisation, RNA manufacture (1-5mg), and the necessary analytics to ensure a high-quality product. RNA manufacture is supported by appropriate quality systems that enable best-practise standards, ensuring documented and robust, scalable processes.
Current production capabilities include:
- pDNA (sub mg to +10 mg)
- mRNA (up to ~100mg)
- Small RNAs (eg. siRNA, 5 to 500 mg)
- Oligo RNA/DNA (up to 100 nt)